Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Rexim is a specialized manufacturer of high-purity amino acids and their derivatives, primarily serving the pharmaceutical, parenteral nutrition, and infant formula industries. Founded in 1955 and based in Ham, France, the company established itself as a global leader in the production of pharmaceutical-grade amino acids. Rexim was acquired by Degussa (now Evonik) and currently operates as a key brand within Evonik's Health Care business line. The company provides a wide range of products including L-amino acids, acetylated amino acids, and specialty salts, all manufactured under strict GMP conditions. Its expertise supports the development of clinical nutrition products and serves as a critical supplier for the synthesis of various pharmaceutical active ingredients.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on 1Rexim.